Research and Development Expenses Breakdown: Sarepta Therapeutics, Inc. vs Corcept Therapeutics Incorporated

Biotech R&D: Sarepta vs. Corcept's Decade of Innovation

__timestampCorcept Therapeutics IncorporatedSarepta Therapeutics, Inc.
Wednesday, January 1, 20141837200094231000
Thursday, January 1, 201515419000146394000
Friday, January 1, 201623844000188272000
Sunday, January 1, 201740376000166707000
Monday, January 1, 201875247000401843000
Tuesday, January 1, 201989017000560909000
Wednesday, January 1, 2020114764000722343000
Friday, January 1, 2021113864000771182000
Saturday, January 1, 2022130991000877090000
Sunday, January 1, 2023184353000877387000
Loading chart...

Unleashing insights

A Decade of Innovation: R&D Spending in Biotech

In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Sarepta Therapeutics, Inc. and Corcept Therapeutics Incorporated have demonstrated contrasting strategies in their R&D investments.

Sarepta's Aggressive Pursuit

Sarepta Therapeutics has consistently outpaced Corcept in R&D spending, with a staggering 830% increase from 2014 to 2023. This aggressive investment reflects their focus on pioneering treatments for rare diseases, particularly in the field of genetic medicine.

Corcept's Steady Growth

In contrast, Corcept Therapeutics has shown a more measured approach, with a 900% increase over the same period. Their focus on developing therapies for metabolic and psychiatric disorders has driven this steady growth.

As these companies continue to innovate, their R&D strategies will be crucial in shaping the future of biotech.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025